Investigation of phosphorylated adjuvants co-encapsulated with a model cancer peptide antigen for the treatment of colorectal cancer and liver metastasis

Tyler J. Goodwin, Leaf Huang

Research output: Research - peer-reviewArticle

  • 3 Citations

Abstract

The lipid calcium phosphate nanoparticle is a versatile platform capable of encapsulating a wide range of phosphorylated molecules from single nucleotides to pDNA. The use of this platform has shown great success as an immunotherapeutic vaccine carrier, capable of delivering co-encapsulated phosphorylated adjuvants and peptides. Three potent vaccine formulations were investigated for anti-cancer efficacy. The phosphorylated adjuvants, CpG, 2′3′cGAMP, and 5′pppdsRNA were co-encapsulated with a model phosphorylated tumor specific peptide antigen (p-AH1-A5). The anti-cancer efficacy of these adjuvants was assessed using an orthotopic colorectal liver metastasis model based on highly aggressive and metastatic CT-26 FL3 cells implanted into the cecum wall. The results clearly indicate that the RIG-1 ligand, 5′pppdsRNA, co-encapsulated with the p-AH1-A5 peptide antigen greatly reduced the growth rate of the primary colon cancer as well as arrested the establishment of liver metastasis in comparison to the other adjuvant formulations and unvaccinated controls. Further evaluation of the immune cell populations within the primary tumor confirms the ability of the 5′pppdsRNA adjuvant to boost the adaptive CD8+ T-cell population, while not inciting increased populations of immune suppressive cell types such as T-regulatory cells or myeloid derived suppressor cells. Furthermore, to our knowledge this is the first study to investigate the anti-cancer efficacy of a specific RIG-1 receptor ligand, 5′pppdsRNA, alongside more established TLR 9 (CpG) and STING (2′3′cGAMP) adjuvants in a cancer vaccine. The 5′pppdsRNA vaccine formulation can be a potent immunotherapy, especially when combined with agents that remodel the immune suppressive microenvironment of the tumor.

LanguageEnglish (US)
Pages2550-2557
Number of pages8
JournalVaccine
Volume35
Issue number19
DOIs
StatePublished - May 2 2017

Fingerprint

Liver Neoplasms
Colorectal Neoplasms
Neoplasm Metastasis
Antigens
Peptides
Neoplasms
colorectal neoplasms
metastasis
adjuvants
peptides
antigens
liver
neoplasms
Vaccines
Population
vaccines
cells
Ligands
Liver
ligands

Keywords

  • 2′3′cGAMP
  • 5′pppdsRNA
  • AH1
  • Colorectal cancer
  • Colorectal liver metastasis
  • CpG
  • Lipid calcium phosphate nanoparticles
  • p-AH1-A5
  • Phosphorylated adjuvants
  • Phosphorylated peptide antigen
  • Vaccine

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

Investigation of phosphorylated adjuvants co-encapsulated with a model cancer peptide antigen for the treatment of colorectal cancer and liver metastasis. / Goodwin, Tyler J.; Huang, Leaf.

In: Vaccine, Vol. 35, No. 19, 02.05.2017, p. 2550-2557.

Research output: Research - peer-reviewArticle

@article{0a144045274d4e0cbfca15d5c85fd6e7,
title = "Investigation of phosphorylated adjuvants co-encapsulated with a model cancer peptide antigen for the treatment of colorectal cancer and liver metastasis",
abstract = "The lipid calcium phosphate nanoparticle is a versatile platform capable of encapsulating a wide range of phosphorylated molecules from single nucleotides to pDNA. The use of this platform has shown great success as an immunotherapeutic vaccine carrier, capable of delivering co-encapsulated phosphorylated adjuvants and peptides. Three potent vaccine formulations were investigated for anti-cancer efficacy. The phosphorylated adjuvants, CpG, 2′3′cGAMP, and 5′pppdsRNA were co-encapsulated with a model phosphorylated tumor specific peptide antigen (p-AH1-A5). The anti-cancer efficacy of these adjuvants was assessed using an orthotopic colorectal liver metastasis model based on highly aggressive and metastatic CT-26 FL3 cells implanted into the cecum wall. The results clearly indicate that the RIG-1 ligand, 5′pppdsRNA, co-encapsulated with the p-AH1-A5 peptide antigen greatly reduced the growth rate of the primary colon cancer as well as arrested the establishment of liver metastasis in comparison to the other adjuvant formulations and unvaccinated controls. Further evaluation of the immune cell populations within the primary tumor confirms the ability of the 5′pppdsRNA adjuvant to boost the adaptive CD8+ T-cell population, while not inciting increased populations of immune suppressive cell types such as T-regulatory cells or myeloid derived suppressor cells. Furthermore, to our knowledge this is the first study to investigate the anti-cancer efficacy of a specific RIG-1 receptor ligand, 5′pppdsRNA, alongside more established TLR 9 (CpG) and STING (2′3′cGAMP) adjuvants in a cancer vaccine. The 5′pppdsRNA vaccine formulation can be a potent immunotherapy, especially when combined with agents that remodel the immune suppressive microenvironment of the tumor.",
keywords = "2′3′cGAMP, 5′pppdsRNA, AH1, Colorectal cancer, Colorectal liver metastasis, CpG, Lipid calcium phosphate nanoparticles, p-AH1-A5, Phosphorylated adjuvants, Phosphorylated peptide antigen, Vaccine",
author = "Goodwin, {Tyler J.} and Leaf Huang",
year = "2017",
month = "5",
doi = "10.1016/j.vaccine.2017.03.067",
volume = "35",
pages = "2550--2557",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "19",

}

TY - JOUR

T1 - Investigation of phosphorylated adjuvants co-encapsulated with a model cancer peptide antigen for the treatment of colorectal cancer and liver metastasis

AU - Goodwin,Tyler J.

AU - Huang,Leaf

PY - 2017/5/2

Y1 - 2017/5/2

N2 - The lipid calcium phosphate nanoparticle is a versatile platform capable of encapsulating a wide range of phosphorylated molecules from single nucleotides to pDNA. The use of this platform has shown great success as an immunotherapeutic vaccine carrier, capable of delivering co-encapsulated phosphorylated adjuvants and peptides. Three potent vaccine formulations were investigated for anti-cancer efficacy. The phosphorylated adjuvants, CpG, 2′3′cGAMP, and 5′pppdsRNA were co-encapsulated with a model phosphorylated tumor specific peptide antigen (p-AH1-A5). The anti-cancer efficacy of these adjuvants was assessed using an orthotopic colorectal liver metastasis model based on highly aggressive and metastatic CT-26 FL3 cells implanted into the cecum wall. The results clearly indicate that the RIG-1 ligand, 5′pppdsRNA, co-encapsulated with the p-AH1-A5 peptide antigen greatly reduced the growth rate of the primary colon cancer as well as arrested the establishment of liver metastasis in comparison to the other adjuvant formulations and unvaccinated controls. Further evaluation of the immune cell populations within the primary tumor confirms the ability of the 5′pppdsRNA adjuvant to boost the adaptive CD8+ T-cell population, while not inciting increased populations of immune suppressive cell types such as T-regulatory cells or myeloid derived suppressor cells. Furthermore, to our knowledge this is the first study to investigate the anti-cancer efficacy of a specific RIG-1 receptor ligand, 5′pppdsRNA, alongside more established TLR 9 (CpG) and STING (2′3′cGAMP) adjuvants in a cancer vaccine. The 5′pppdsRNA vaccine formulation can be a potent immunotherapy, especially when combined with agents that remodel the immune suppressive microenvironment of the tumor.

AB - The lipid calcium phosphate nanoparticle is a versatile platform capable of encapsulating a wide range of phosphorylated molecules from single nucleotides to pDNA. The use of this platform has shown great success as an immunotherapeutic vaccine carrier, capable of delivering co-encapsulated phosphorylated adjuvants and peptides. Three potent vaccine formulations were investigated for anti-cancer efficacy. The phosphorylated adjuvants, CpG, 2′3′cGAMP, and 5′pppdsRNA were co-encapsulated with a model phosphorylated tumor specific peptide antigen (p-AH1-A5). The anti-cancer efficacy of these adjuvants was assessed using an orthotopic colorectal liver metastasis model based on highly aggressive and metastatic CT-26 FL3 cells implanted into the cecum wall. The results clearly indicate that the RIG-1 ligand, 5′pppdsRNA, co-encapsulated with the p-AH1-A5 peptide antigen greatly reduced the growth rate of the primary colon cancer as well as arrested the establishment of liver metastasis in comparison to the other adjuvant formulations and unvaccinated controls. Further evaluation of the immune cell populations within the primary tumor confirms the ability of the 5′pppdsRNA adjuvant to boost the adaptive CD8+ T-cell population, while not inciting increased populations of immune suppressive cell types such as T-regulatory cells or myeloid derived suppressor cells. Furthermore, to our knowledge this is the first study to investigate the anti-cancer efficacy of a specific RIG-1 receptor ligand, 5′pppdsRNA, alongside more established TLR 9 (CpG) and STING (2′3′cGAMP) adjuvants in a cancer vaccine. The 5′pppdsRNA vaccine formulation can be a potent immunotherapy, especially when combined with agents that remodel the immune suppressive microenvironment of the tumor.

KW - 2′3′cGAMP

KW - 5′pppdsRNA

KW - AH1

KW - Colorectal cancer

KW - Colorectal liver metastasis

KW - CpG

KW - Lipid calcium phosphate nanoparticles

KW - p-AH1-A5

KW - Phosphorylated adjuvants

KW - Phosphorylated peptide antigen

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=85016564123&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016564123&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2017.03.067

DO - 10.1016/j.vaccine.2017.03.067

M3 - Article

VL - 35

SP - 2550

EP - 2557

JO - Vaccine

T2 - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 19

ER -